Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Increased by Woodline Partners LP

Woodline Partners LP grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,120,922 shares of the company's stock after acquiring an additional 16,977 shares during the period. Vaxcyte comprises approximately 0.6% of Woodline Partners LP's holdings, making the stock its 20th biggest holding. Woodline Partners LP owned about 0.90% of Vaxcyte worth $91,759,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PCVX. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte in the 4th quarter valued at $28,000. Smartleaf Asset Management LLC raised its stake in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after acquiring an additional 260 shares during the period. National Bank of Canada FI purchased a new position in shares of Vaxcyte in the 4th quarter valued at $41,000. Blue Trust Inc. raised its stake in shares of Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after acquiring an additional 371 shares during the period. Finally, Assetmark Inc. raised its stake in shares of Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.10% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PCVX shares. The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Bank of America dropped their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Trading Down 4.2%

PCVX stock traded down $1.41 during mid-day trading on Friday, hitting $32.54. 1,763,863 shares of the company were exchanged, compared to its average volume of 1,371,448. The company has a market capitalization of $4.20 billion, a PE ratio of -7.07 and a beta of 1.27. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The firm has a fifty day simple moving average of $38.53 and a 200 day simple moving average of $69.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the business earned ($0.85) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.